ARCHIVES

Phase II Elotuzumab Study Demonstrates 33 Months PFS

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

House Passes Cancer Bill With Mandates for NCI

September 28, 2012

Newell, Fredrickson Question Ethics Of Laetrile Trials

July 22, 1977

Also Kevin Cullen named director, Univ. of Maryland Greenebaum Cancer Center.

November 28, 2003

FDA Approves Tamoxifen For DCIS Folowing Breast Surgery And Radiation.

July 28, 2000

BSA Eliminates Second Review For P01 Grants; R01Payline To increase to 24th Percentile

November 23, 1997

O’Neill Account, Kennedy Hearing, Create Climate On Capitol Hill for Increasing Cancer Funding

May 3, 1991